Keywords
Cannabidiol
Oral ulcer
Pathology, oral
How to Cite
Abstract
Aim: This study aims to analyze the potential therapeutic effect of cannabidiol use on oral mucosa lesions in clinical and in vivo studies. Methods: A scoping review was conducted considering the question: “Is there a therapeutic effect of the use of cannabidiol (CBD) on lesions of the oral mucosa?”. Four distinct databases were searched (PubMed/MEDLINE, Embase, Web of Science, and Scopus) and gray literature until August 2023. Original clinical and in vivo studies were included, involving human and animal subjects where CBD was applied topically to the oral mucosa or administered systemically for the treatment of lesions or superficial/deep alterations of the oral mucosa. Results: A total of 610 records were found in the initial searches. Twelve studies were assessed in full text for eligibility and five studies were excluded. Seven studies were included in this review. Five studies were conducted with in vivo design and only two studies had clinical design in humans. Considering results from in vivo studies, all of them presented better clinical results for oral mucosa lesion groups treated with CBD-based therapy compared to placebo. Regarding histological features, four studies found statistically significant improvement in CBD-based therapy and only one study did not find a significant improvement. For clinical studies, all studies presented positive clinical results (primarily regarding pain control) in the use of CBD-based therapies. Conclusion: CBD appears effective in treating oral mucosa lesions (oral mucositis, ulcers, burning mouth syndrome). CBD-based therapies can reduce inflammation in vivo studies and hold promise for pain control and lesion healing in oral mucosa lesions in clinical studies. However, the limited number of clinical trials, heterogeneity in cannabis-based therapies, and a lack of standardized protocols underscore the need for further rigorous, interdisciplinary research to establish consistent dosing and assess the efficacy of various cannabinoids in treating oral mucosa conditions.
References
Pruyn SA, Wang Q, Wu CG, Taylor CL. Quality standards in state programs permitting cannabis for medical uses. Cannabis Cannabinoid Res. 2022 Dec;7(6):728-35. doi: 10.1089/can.2021.0164.
Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic potential of Cannabis, cannabidiol, and cannabinoid-based pharmaceuticals. Pharmacology. 2022;107(3-4):131-49. doi: 10.1159/000521683.
Good P, Haywood A, Gogna G, Martin J, Yates P, Greer R, et al. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD). BMC Palliat Care. 2019 Dec;18(1):110. doi: 10.1186/s12904-019-0494-6.
Peyravian N, Deo S, Daunert S, Jimenez JJ. The anti-inflammatory effects of cannabidiol (CBD) on acne. J Inflamm Res. 2022 May;15:2795-801. doi: 10.2147/JIR.S355489.
Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015 Apr;23(7):1377-85. doi: 10.1016/j.bmc.2015.01.059.
Petrovici AR, Simionescu N, Sandu AI, Paraschiv V, Silion M, Pinteala M. New insights on hemp oil enriched in cannabidiol: decarboxylation, antioxidant properties and in vitro anticancer effect. Antioxidants (Basel). 2021 May;10(5):738. doi: 10.3390/antiox10050738.
Volmar MNM, Cheng J, Alenezi H, Richter S, Haug A, Hassan Z, et al. Cannabidiol converts NF-kappaB into a tumor suppressor in glioblastoma with defined antioxidative properties. Neuro Oncol. 2021 Nov;23(11):1898-910. doi: 10.1093/neuonc/noab095.
Urits I, Gress K, Charipova K, Habib K, Lee D, Lee C, et al. Use of cannabidiol (CBD) for the treatment of chronic pain. Best Pract Res Clin Anaesthesiol. 2020 Sep;34(3):463-77. doi: 10.1016/j.bpa.2020.06.004.
Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010 Feb;39(2):167-79. doi: 10.1016/j.jpainsymman.2009.06.008. Epub 2009 Nov 5.
Gaisberger M, Fuchs J, Riedl M, Edtinger S, Reischl R, Grasmann G, et al. Endogenous anandamide and self-reported pain are significantly reduced after a 2-week multimodal treatment with and without radon therapy in patients with knee osteoarthritis: a pilot study. Int J Biometeorol. 2021 Jul;65(7):1151-60. doi: 10.1007/s00484-021-02095-z.
You T, Disanzo BL, Wang X, Yang R, Gong D. Adipose tissue endocannabinoid system gene expression: depot differences and effects of diet and exercise. Lipids Health Dis. 2011 Oct;10:194. doi: 10.1186/1476-511X-10-194.
van Hell HH, Jager G, Bossong MG, Brouwer A, Jansma JM, Zuurman L, et al. Involvement of the endocannabinoid system in reward processing in the human brain. Psychopharmacology (Berl). 2012 Feb;219(4):981-90. doi: 10.1007/s00213-011-2428-8. Epub 2011 Aug 6.
Gambino A, Cabras M, Panagiotakos E, Calvo F, Macciotta A, Cafaro A, et al. Evaluating the suitability and potential efficiency of cannabis sativa oil for patients with primary burning mouth syndrome: a prospective, open-label, single-arm pilot study. Pain Med. 2021 Feb;22(1):142-51. doi: 10.1093/pm/pnaa318.
Shiplo S, Asbridge M, Leatherdale ST, Hammond D. Medical cannabis use in Canada: vapourization and modes of delivery. Harm Reduct J. 2016 Oct;13(1):30. doi: 10.1186/s12954-016-0119-9.
Fitzcharles MA, Rampakakis E, Sampalis JS, Shir Y, Cohen M, Starr M, et al. Use of medical cannabis by patients with fibromyalgia in Canada after cannabis legalisation: a cross-sectional study. Clin Exp Rheumatol. 2021 May-Jun;39 Suppl 130(3):115-9. doi: 10.55563/clinexprheumatol/qcyet7.
Chisini LA, Cademartori MG, Francia A, Mederos M, Grazioli G, Conde MCM, et al. Is the use of cannabis associated with periodontitis? A systematic review and meta-analysis. J Periodontal Res. 2019 Aug;54(4):311-7. doi: 10.1111/jre.12639.
Qi X, Lin W, Wu Y, Li Q, Zhou X, Li H, et al. CBD Promotes oral ulcer healing via inhibiting CMPK2-Mediated inflammasome. J Dent Res. 2022 Feb;101(2):206-15. doi: 10.1177/00220345211024528. Epub 2021 Jul 16.
Liu Y, Qi X, Wang Y, Li M, Yuan Q, Zhao Z. Inflammation-targeted cannabidiol-loaded nanomicelles for enhanced oral mucositis treatment. Drug Deliv. 2022 Dec;29(1):1272-81. doi: 10.1080/10717544.2022.2027572.
Maida V, Corban J. Topical medical cannabis: a new treatment for wound pain-three cases of pyoderma gangrenosum. J Pain Symptom Manage. 2017 Nov;54(5):732-6. doi: 10.1016/j.jpainsymman.2017.06.005.
Chelliah MP, Zinn Z, Khuu P, Teng JMC. Self-initiated use of topical cannabidiol oil for epidermolysis bullosa. Pediatr Dermatol. 2018 Jul;35(4):e224-7. doi: 10.1111/pde.13545.
Lowe H, Toyang N, Steele B, Bryant J, Ngwa W, Nedamat K. The current and potential application of medicinal cannabis products in dentistry. Dent J (Basel). 2021 Sep;9(9):106. doi: 10.3390/dj9090106.
David C, Elizalde-Hernandez A, Barboza AS, Cardoso GC, Santos MBF, Moraes RR. Cannabidiol in dentistry: a scoping review. Dent J (Basel). 2022 Oct;10(10):193. doi: 10.3390/dj10100193.
Kongkadee K, Wisuitiprot W, Ingkaninan K, Waranuch N. Anti-inflammation and gingival wound healing activities of Cannabis sativa L. subsp. sativa (hemp) extract and cannabidiol: an in vitro study. Arch Oral Biol. 2022 Aug;140:105464. doi: 10.1016/j.archoralbio.2022.105464.
Wen SD, Sans-Serramitjana E, Santander JF, Sanchez MR, Salazar-Aguilar P, Zepeda AB, et al. Effects of natural extracts in the treatment of oral ulcers: a systematic review of evidence from experimental studies in animals. J Clin Exp Dent. 2021 Oct;13(10):e1038-48. doi: 10.4317/jced.58567.
Moghadam ET, Yazdanian M, Tahmasebi E, Tebyanian H, Ranjbar R, Yazdanian A, et al. Current herbal medicine as an alternative treatment in dentistry: in vitro, in vivo and clinical studies. Eur J Pharmacol. 2020 Dec;889:173665. doi: 10.1016/j.ejphar.2020.173665.
Gharibpour F, Shirban F, Bagherniya M, Nosouhian M, Sathyapalan T, Sahebkar A. The effects of nutraceuticals and herbal medicine on Candida albicans in oral candidiasis: a comprehensive review. Adv Exp Med Biol. 2021;1308:225-48. doi: 10.1007/978-3-030-64872-5_16.
Cuba LF, Salum FG, Cherubini K, Figueiredo MAZ. Cannabidiol: an alternative therapeutic agent for oral mucositis? J Clin Pharm Ther. 2017 Jun;42(3):245-50. doi: 10.1111/jcpt.12504.
Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018 Oct;169(7):467-73. doi: 10.7326/M18-0850.
Tricco AC, Lillie E, Zarin W, O'Brien K, Colquhoun H, Kastner M, et al. A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol. 2016 Feb;16:15. doi: 10.1186/s12874-016-0116-4.
Chisini LA, Conde MCM, Grazioli G, Martin ASS, Carvalho RV, Nor JE, et al. Venous blood derivatives as FBS-Substitutes for mesenchymal stem cells: a systematic scoping review. Braz Dent J. 2017 Nov-Dec;28(6):657-68. doi: 10.1590/0103-6440201701646.
Chisini LA, Conde MCM, Grazioli G, Martin ASS, Carvalho RV, Sartori LRM, et al. Bone, periodontal and dental pulp regeneration in dentistry: a systematic scoping review. Braz Dent J. 2019 Mar-Apr;30(2):77-95. doi: 10.1590/0103-6440201902053.
Conde MCM, Chisini LA, Sarkis-Onofre R, Schuch HS, Nor JE, Demarco FF. A scoping review of root canal revascularization: relevant aspects for clinical success and tissue formation. Int Endod J. 2017 Sep;50(9):860-74. doi: 10.1111/iej.12711. Epub 2016 Dec 3.
Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015 Sep;13(3):141-6. doi: 10.1097/XEB.0000000000000050.
Darling MR, Arendorf TM, Coldrey NA. Effect of cannabis use on oral candidal carriage. J Oral Pathol Med. 1990 Aug;19(7):319-21. doi: 10.1111/j.1600-0714.1990.tb00852.x.
Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol. 2013 Jan;260(1):285-95. doi: 10.1007/s00415-012-6634-z.
Jiménez-Rodríguez C, Santana-del-Pino A, Jiménez-Díaz JF, Hernández-Martínez F, Rodríguez-de-Vera BC. Cutaneous ulceration scattering induced topically by cannabidiol oil in the laboratory animal. Eur J Public Health. 2019 Apr;29(Suppl 1):ckz034.017. doi: 10.1093/eurpub/ckz034.017.
Klein M, de Quadros De Bortolli J, Guimaraes FS, Salum FG, Cherubini K, de Figueiredo MAZ. Effects of cannabidiol, a Cannabis sativa constituent, on oral wound healing process in rats: clinical and histological evaluation. Phytother Res. 2018 Nov;32(11):2275-81. doi: 10.1002/ptr.6165.
Cuba LF, Salum FG, Guimaraes FS, Cherubini K, Borghetti RL, de Figueiredo MAZ. Cannabidiol on 5-FU-induced oral mucositis in mice. Oral Dis. 2020 Oct;26(7):1483-93. doi: 10.1111/odi.13413.
Li L, Xuan Y, Zhu B, Wang X, Tian X, Zhao L, et al. Protective effects of cannabidiol on chemotherapy-induced oral mucositis via the Nrf2/Keap1/ARE signaling pathways. Oxid Med Cell Longev. 2022 May;2022:4619760. doi: 10.1155/2022/4619760.
Umpreecha C, Bhalang K, Charnvanich D, Luckanagul J. Efficacy and safety of topical 0.1% cannabidiol for managing recurrent aphthous ulcers: a randomized controlled trial. BMC Complement Med Ther. 2023 Feb;23(1):57. doi: 10.1186/s12906-023-03886-0.
Mlost J, Bryk M, Starowicz K. Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. Int J Mol Sci. 2020 Nov;21(22). doi: 10.3390/ijms21228870.
Conejero Del Mazo R, Garcia Forcen L, Navarro Aguilar ME. Recurrent aphthous stomatitis. Med Clin (Barc). 2023 Sep;161(6):251-9. doi: 10.1016/j.medcli.2023.05.007.
McMillan R, Forssell H, Buchanan JA, Glenny AM, Weldon JC, Zakrzewska JM. Interventions for treating burning mouth syndrome. Cochrane Database Syst Rev. 2016 Nov;11(11):CD002779. doi: 10.1002/14651858.CD002779.pub3.
de Meneses AG, Normando AGC, Porto de Toledo I, Reis PED, Guerra ENS. Effects of oral supplementation in the management of oral mucositis in cancer patients: a meta-analysis of randomized clinical trials. J Oral Pathol Med. 2020 Feb;49(2):117-25. doi: 10.1111/jop.12901. Epub 2019 Jun 25.
Mimura MA, Hirota SK, Sugaya NN, Sanches JA Jr, Migliari DA. Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial. Clinics (Sao Paulo). 2009;64(3):193-8. doi: 10.1590/s1807-59322009000300008.
Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017 Nov;39(11):2216-29. doi: 10.1016/j.clinthera.2017.09.011.
Schräder NHB, Duipmans JC, Molenbuur B, Wolff AP, Jonkman MF. Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases. Br J Dermatol. 2019 Apr;180(4):922-4. doi: 10.1111/bjd.17341. Epub 2018 Nov 14.
Perez E, Fernandez JR, Fitzgerald C, Rouzard K, Tamura M, Savile C. In vitro and clinical evaluation of cannabigerol (CBG) produced via yeast biosynthesis: a cannabinoid with a broad range of anti-inflammatory and skin health-boosting properties. Molecules. 2022 Jan;27(2). doi: 10.3390/molecules27020491.
Tijani AO, Thakur D, Mishra D, Frempong D, Chukwunyere UI, Puri A. Delivering therapeutic cannabinoids via skin: current state and future perspectives. J Control Release. 2021 Jun;334:427-51. doi: 10.1016/j.jconrel.2021.05.005.
Shao K, Stewart C, Grant-Kels JM. Cannabis and the skin. Clin Dermatol. 2021 Sep-Oct;39(5):784-95. doi: 10.1016/j.clindermatol.2021.05.006.
Scully C. Cannabis; adverse effects from an oromucosal spray. Br Dent J. 2007 Sep 22;203(6):E12; discussion 336-7. doi: 10.1038/bdj.2007.749.
Nitecka-Buchta A, Nowak-Wachol A, Wachol K, Walczynska-Dragon K, Olczyk P, Batoryna O, et al. Myorelaxant effect of transdermal cannabidiol application in patients with TMD: a randomized, double-blind trial. J Clin Med. 2019 Nov;8(11):1886. doi: 10.3390/jcm8111886.
Bhaskar A, Bell A, Boivin M, Briques W, Brown M, Clarke H, et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. J Cannabis Res. 2021 Jul;3(1):22. doi: 10.1186/s42238-021-00073-1.
Suharyani I, Fouad Abdelwahab Mohammed A, Muchtaridi M, Wathoni N, Abdassah M. Evolution of drug delivery systems for recurrent aphthous stomatitis. Drug Des Devel Ther. 2021 Sep;15:4071-89. doi: 10.2147/DDDT.S328371.
Paderni C, Compilato D, Giannola LI, Campisi G. Oral local drug delivery and new perspectives in oral drug formulation. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Sep;114(3):e25-34. doi: 10.1016/j.oooo.2012.02.016.
Dommisch H, Stolte KN, Jager J, Vogel K, Müller R, Hedtrich S, et al. Characterization of an ester-based core-multishell (CMS) nanocarrier for the topical application at the oral mucosa. Clin Oral Investig. 2021 Oct;25(10):5795-805. doi: 10.1007/s00784-021-03884-x.
Moghadamnia AA, Motallebnejad M, Khanian M. The efficacy of the bioadhesive patches containing licorice extract in the management of recurrent aphthous stomatitis. Phytother Res. 2009 Feb;23(2):246-50. doi: 10.1002/ptr.2601.
Sosnik A, Seremeta KP. Polymeric hydrogels as technology platform for drug delivery applications. Gels. 2017 Jul;3(3):25. doi: 10.3390/gels3030025.
Jager J, Obst K, Lohan SB, Viktorov J, Staufenbiel S, Renz H, et al. Characterization of hyperbranched core-multishell nanocarriers as an innovative drug delivery system for the application at the oral mucosa. J Periodontal Res. 2018 Feb;53(1):57-65. doi: 10.1111/jre.12487. Epub 2017 Sep 12.
Gao MS, Liu S, Wang AW. [Preparation and clinical observation of Koukuining granules in 50 patients with recurrent aphthous ulcer]. Shanghai Kou Qiang Yi Xue. 2016 Oct;25(5):579-82. Chinese.
Junaid MSA, Tijani AO, Puri A, Banga AK. In vitro percutaneous absorption studies of cannabidiol using human skin: exploring the effect of drug concentration, chemical enhancers, and essential oils. Int J Pharm. 2022 Mar;616:121540. doi: 10.1016/j.ijpharm.2022.121540.
Kirk RD, Akanji T, Li H, Shen J, Allababidi S, Seeram NP, et al. Evaluations of skin permeability of cannabidiol and its topical formulations by skin membrane-based parallel artificial membrane permeability assay and Franz cell diffusion assay. Med Cannabis Cannabinoids. 2022 Oct;5(1):129-37. doi: 10.1159/000526769.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Matias Mederos, Luana Carla Salvi, Luiz Alexandre Chisini
Downloads
